Cost-effectiveness analysis of a hypothetical vaccine for schistosomiasis in Madagascar and Burkina Faso
Vaccine·
- DOI
- 10.1016/j.vaccine.2026.128936
- PMID
- 42447735
- PMCID
- —
- OpenAlex
- W7168279250
- Study type
- Journal article
- Publisher
- Elsevier BV
- Article type
- journal-article
- Integrity
- current
Why this research matters now
The modeling results suggest that integrating adult demographics into future immunization campaigns could optimize resource allocation and disease reduction in highly affected regions. Policymakers might consider these economic parameters when planning next-generation preventive tools against this parasitic infection.
Structured evidence summary
Research question
What is the economic viability of different hypothetical schistosomiasis vaccination approaches compared to standard care in two endemic regions?
Study design
The investigation utilized a computational Markov modeling approach to simulate health and financial outcomes across different intervention scenarios.
Population and setting
The analysis focused on disease-endemic populations within Madagascar and Burkina Faso, incorporating age-stratified epidemiological data.
Main findings
Targeting only school-aged youth typically failed to meet cost-effectiveness thresholds, whereas expanding coverage to adults significantly enhanced economic value. The optimal hypothetical regimen demonstrated strong financial returns in one nation and achieved both superior health outcomes and reduced expenditures in the other. Protection longevity proved more critical than initial potency, while per-dose pricing heavily impacted overall viability.
Public-health relevance
The modeling results suggest that integrating adult demographics into future immunization campaigns could optimize resource allocation and disease reduction in highly affected regions. Policymakers might consider these economic parameters when planning next-generation preventive tools against this parasitic infection.
Important limitations
The assessment depends on simulated Markov modeling rather than empirical clinical trials, and the evaluated immunization profiles remain theoretical. Economic calculations rely on external field-derived datasets that may not fully reflect actual programmatic expenses.
GIDS interpretation
This work functions as a theoretical economic evaluation intended to inform future health technology assessments for neglected tropical diseases. Its methodological focus on modeled cost-effectiveness provides background context for policy planning rather than contributing to active outbreak tracking or real-time disease monitoring.
Related GIDS surveillance
Literature context does not validate, explain, or change a surveillance signal. Exact and contextual relationships are shown separately.
Evidence relationships
This article has 14 auditable classifier relationships to diseases, places, topics, and study design.